Lucentis for New Onset Neovascular Glaucoma

Study Overview
=================
Brief Summary
-----------------
Neovascular glaucoma is a potentially debilitating disease of the eye. Vascular eye disease such as diabetes and vein occlusions can cause the retina to release factors that promote the growth of abnormal blood vessels. These abnormal vessels can grow in the drainage mechanism of the eye causing pressure in the eye to markedly increase. This can potentially cause irreversible damage to the optic nerve from glaucoma leading to permanent blindness and painful eyes. Conventional treatments including laser and freezing therapy take weeks to cause regression in abnormal blood vessel growth. This delay often results in permanent vision loss and pain. New medications targeted at more immediately reducing blood vessel growth may aid in the treatment of this disease.

Detailed Description
-----------------
Hypothesis: Intravitreal injection of Lucentis prior to conventional treatment for neovascular glaucoma improves overall outcome compared to conventional treatment alone. Specific Aims: To determine if pre-treatment with a single intravitreal injection of Lucentis prior to conventional treatment prevents severe vision loss and improves intraocular pressure control compared to conventional treatment alone. Neovascular glaucoma is a potentially devastating consequence of fibrovascular proliferation of the anterior chamber angle with subsequent obstruction of the trabecular meshwork. The production of peripheral anterior synechiae along the trabecular meshwork leads to progressive angle closure. The subsequent elevation in intraocular pressure is difficult to manage, often leading to rapid progression of glaucoma and significant loss of vision. Enucleation for blind, painful eyes secondary to neovascular glaucoma is not an uncommon sequelae. Neovascular glaucoma has many etiologic causes, the vast majority resulting from retinal ischemia secondary to relatively common diseases such as central retinal vein occlusion, proliferative diabetic retinopathy and ocular ischemic syndrome (carotid stenosis). (Sivac-Callcott et al., 2001) Vascular endothelial growth factor is likely a major contributor to the development of angle and iris neovascularization. (Ferrara, 2004) Although panretinal photocoagulation and/or cryoablation are mainstays of conventional treatment for neovascular glaucoma, the delayed therapeutic effect of these interventions often results in the formation of peripheral anterior synechiae and permanent angle closure. Recent limited case series have demonstrated a role for bevacizumab (Avastin) in reducing rubeosis iridis and as an adjunct for neovascular glaucoma. (Grisanti et al., 2006; Davidorf et al., 2006; Iliev et al., 2006; Kahook, Schuman, Noecker, 2006) However, no prospective studies have examined the potential utility of anti-vascular endothelial growth factor agents in the treatment of neovascular glaucoma. Intravitreal Lucentis is the standard of care for the treatment of exudative macular degeneration. Pharmacologic agents such as Lucentis, which selectively inhibit vascular endothelial growth factor may provide an important therapeutic adjunct for the treatment of neovascular glaucoma by more immediately causing regression of angle neovascularization and thereby providing a window for permanent treatment with laser or cryotherapy.

Official Title
-----------------
Randomized Controlled Trial of Lucentis in the Management of New Onset Neovascular Glaucoma

Conditions
-----------------
Glaucoma, New Onset Glaucoma, Neovascular Glaucoma, New Onset Neovascular Glaucoma

Intervention / Treatment
-----------------
* Drug: Ranibizumab (Lucentis)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to provide written informed consent and comply with study assessments for the full duration of the study Age > 21 years Diagnosis of neovascular glaucoma (angle neovascularization with or without iris neovascularization and IOP > 21 mm Hg and > 5 mm Hg IOP compared to the fellow eye). Neovascular glaucoma secondary to retinal ischemia (central retinal vein occlusion, proliferative diabetic retinopathy, ocular ischemic syndrome, etc.) Exclusion Criteria: Pregnancy (positive pregnancy test) or lactation or pre-menopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch. Prior enrollment in the study Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated Participation in another simultaneous medical investigation or trial > 270 degrees of closed trabecular meshwork (closure secondary to peripheral anterior synechiae) History of active inflammatory, infectious, or idiopathic keratitis precluding view of the anterior segment structures. Previous intravitreal injections of ranibizumab or bevacizumab in either eye.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Lucentis (ranibizumab) with conventional treatment | Drug: Ranibizumab (Lucentis)<br>* 0.5 mg ranibizumab intravitreal injection single dose administration<br>* Other names: Lucentis;|
| No Intervention: 2<br>Conventional treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change in best corrected visual acuity (BCVA) as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters from baseline to Month 6. |  | Baseline to Month 6. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent change in angle neovascularization (measured in clock hours by gonioscopy). |  | Initial visit through Month 6 | 
| Percent change in permanent angle closure (clock hours of peripheral anterior synechiae by gonioscopy). |  | Initial visit through Month 6 | 
| Mean change in intraocular pressure measured by applanation tonometry. |  | Initial visit through Month 6 | 
| Percent change in iris neovascularization (measured both in clock hours by slit lamp exam and with iris angiography). |  | Initial visit through Month 6 | 
| Rates of severe vision loss (visual acuity <20/200, loss of 6 lines or more on ETDRS chart). |  | Initial Visit through Month 6 | 
| Number of intraocular pressure lowering medications needed to control intraocular pressure. |  | Initial Visit through Month 6 | 
| Mean change in optic nerve cupping. |  | Initial Visit through Month 6 | 
| Percent of patients requiring surgical glaucoma procedure to control intraocular pressure (trabeculectomy, seton, or ciliary body destruction). |  | Study duration | 
| Percent of patients requiring pars plana vitrectomy with endolaser. |  | Study duration | 
| Rates of endophthalmitis. |  | Study duration | 
| Rates of rhegmatogenous retinal detachment. |  | Study duration | 
| Final clock hours of permanent angle closure (clock hours of peripheral anterior synechiae by gonioscopy) |  | Month 6 visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glaucoma, neovascular glaucoma, new onset glaucoma, retinal ischemia, central retinal vein occlusion, proliferative diabetic retinopathy, ocular ischemic syndrome, carotid stenosis, vascular endothelial growth factor, neovascular